STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) Is the Biggest Big Enough?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Kaski, Juan Carlos & Cockerill, Gillian W.
S
A
R
I
J
G
L
T
c
d
a
i
M
r
u
i
e
r
d
t
R
D
a
t
i
t
(
e
I
R
T
a
a
R
m
h
u
e
t
s
h
m
u
fi
t
t
a
g
v
r
m
a
p
i
r
d
e
b
b
S
z
4
o
w
(
m
i
s
i
a
S
p
r
u
F
(
l
p
s
d
o
e
s
R
C
*
v
A
a
Journal of the American College of Cardiology Vol. 53, No. 22, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2009.02.034EDITORIAL COMMENT
TARR (STudy of
therosclerosis with
amipril and Rosiglitazone)
s the Biggest Big Enough?*
uan Carlos Kaski, MD, DM (HONS), DSC,
illian W. Cockerill, PHD
ondon, United Kingdom
he relationship between elevated plasma glucose levels and
ardiovascular (CV) risk has been confirmed by studies
emonstrating that individuals with impaired glucose toler-
nce (IGT) or impaired fasting glucose (IFG) have an
ncreased likelihood of developing major CV events (1).
See page 2028
etabolic abnormalities such as diabetes, obesity, insulin
esistance, and dyslipidemia predispose to atherosclerosis
sually via mechanisms involving endothelial activation,
nflammation, increased oxidative stress, and thrombogen-
sis (2). There is a need for effective strategies to reduce CV
isk in subjects with early manifestations of these metabolic
isorders. In this issue of the Journal, Lonn et al. (3) report
he results of the STARR (STudy of Atherosclerosis with
amipril and Rosiglitazone), a challenging substudy of the
REAM (Diabetes REduction Assessment with ramipril
nd rosiglitazone Medication) trial (4), aimed at assessing
he effects of the angiotensin-converting enzyme (ACE)
nhibitor ramipril and the thiazolidinedione (TZD) rosigli-
azone on the progression of carotid intima-media thickness
CIMT), in patients with pre-diabetes but without clinical
vidence for CV disease.
mportance of Defining a Therapeutic
egimen in the Pre-Diabetic Population
he rationale for the study is sound in that both ramipril
nd rosiglitazone have a wide range of properties that could
fford vasculoprotection in patients with pre-diabetes.
amipril has been shown to reduce the incidence of stroke,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Cardiovascular Biology and Surgery Research Centre, Division of Cardiac
nd Vascular Sciences, St George’s, University of London, London, United Kingdom.yocardial infarction (MI), and death due to CV disease in
igh-risk patient groups (5). These beneficial effects are
sually attributed to mean arterial pressure reduction. How-
ver, studies in humans and experimental animals indicate
hat ACE inhibitors have additional effects on arterial wall
tructure contributing to reduced arterial stiffness. Ramipril
as been shown to influence the expression and synthesis of
atrix components, collagens and elastin, and matrix mod-
lating enzymes (i.e., metalloproteinase-2 and -3). These
ndings lend support to the argument that the vasculopro-
ective effects of ACE inhibitors might also be secondary to
hese molecular changes (6).
The TZDs, peroxisome proliferators-activated receptor
ctivators, are a family of drugs known to influence both
lucose and lipid metabolism through transcriptional acti-
ation of specific genes. In addition, these agents have a
ange of cellular effects that are independent of their
etabolic effects. The TZDs have anti-inflammatory and
nti-atherogenic properties and inhibit smooth muscle cell
roliferation, thus providing a mechanism for these drugs to
nfluence medial hyperplasia (7). These observations and
ecent findings of atheroma reduction in patients with
iabetes (8,9) as well as the demonstration of beneficial
ffects of rosiglitazone on CIMT progression in a nondia-
etic population (10) support the idea that the effect might
e independent of the metabolic actions of TZDs.
Although both pharmacological agents used in the
TARR trial are well known, the clinical use of rosiglita-
one has recently come into question after a meta-analysis of
2 trials that showed that, as compared with placebo or
ther antidiabetic regimens, treatment with rosiglitazone
as associated with an increased risk of MI and CV death
11). The worrisome findings in the Nissen and Wolski
eta-analysis (11), however, need to be further investigated
n prospective studies, because they were of borderline
tatistical significance and were based both on limited
nformation from trial results obtained from publicly avail-
ble sources and on a relatively small number of events. The
TARR trial, which assessed a population of pre-diabetic
atients with a therapeutic need for preventative drug
egimens, did not find differences in CV event rates with the
se of rosiglitazone during a median follow-up of 3 years.
urther to this issue, an interim report of the RECORD
Rosiglitazone Evaluated for Cardiac Outcomes and Regu-
ation of Glycaemia in Diabetes) study, a well-designed
rospective study of 4,447 patients with diabetes, has not
hown a significant increase in the incidence of MI or CV
eath or in the combined primary end point of hospital stay
r death from CV causes with rosiglitazone (12). The final
valuation, however, awaits the report of the 3 large pro-
pective trials (RECORD, BARI2D [Bypass Angioplasty
evascularization Investigation 2 Diabetes], and AC-
ORD [Action to Control Cardiovascular Risk in Diabe-
es]) to provide a definitive answer.
T
M
M
r
p
m
o
fi
t
t
d
m
e
S
b
d
l
r
s
l
(
o
i
d
t
p
t
s
i
S
a
p
p
t
s
t
s
d
a
t
n
e
b
t
q
o
s
i
c
o
C
r
r
(
v
r
o
e
i
e
m
d
P
t
t
o
i
i
R
C
C
j
R
2037JACC Vol. 53, No. 22, 2009 Kaski and Cockerill
June 2, 2009:2036–8 STARR: Is the Biggest Big Enough?he STARR Trial: Surrogate Markers,
ain Findings, and Clinical Implications
ain findings in the STARR trial (3) were that ramipril
educed blood pressure and had a neutral effect on CIMT
rogression, whereas rosiglitazone reduced glycemia and had a
odest beneficial action on CIMT progression. The absence
f a significant effect of ramipril on CIMT contrasts with
ndings in previous studies showing that ACE inhibitor
reatment reduces CIMT progression (13). However, such
rials were conducted in high-risk populations with vascular
isease, diabetes, or hypertension who are expected to have a
ore active renin-angiotensin system and rapid vascular dis-
ase progression, compared with the subjects entered in the
TARR trial. The results for rosiglitazone are not conclusive
ut suggest a modest beneficial short-term effect on vascular
isease progression that could perhaps result in more robust
onger-term effects on vascular disease progression.
CIMT, a surrogate end point for the estimation of future
isk of CV events, is a validated end point and has been
hown to correlate with risk of future CV events (14). The
ow CIMT progression rates observed in the STARR trial
3) contrast with other reports that showed an increased rate
f CV events in subjects with pre-diabetes compared with
ndividuals with normal glucose metabolism. An important
ifference between the STARR trial and other studies is
hat patients in the latter group were followed for longer
eriods of time (13), and this could explain, at least in part,
he discrepancies. Moreover, the STARR investigators
eem to have overestimated the expected CIMT progression
n their study (by approximately 50%), which meant that the
TARR participants had a far lower CIMT progression,
nd thus the ability to observe a 30% inhibitory effect in a
opulation comprising only 1,425 patients might be com-
romised. The authors suggest that this might account for
he unexpected lack of effect of ramipril. Previous trials
howing a beneficial effect of ramipril were studies in which
he extent of baseline CIMT was greater (13).
The trial is challenging both from the point of view of the
ize and length of the study and the ability to measure a
rug effect on CIMT, a parameter with low baseline values
nd unlikely to change significantly over a relatively short
erm in a population where progression of CV disease does
ot necessarily follow an accelerated course.
The STARR trial (3) is the largest of its kind thus far to
xamine CIMT progression in individuals with IGT or IFG
ut without CV disease. In addition, the trial can also claim
hat it has the longest period of observation, 3.09 (inter-
uartile range 2.86 to 3.50) years, in comparison with
ther studies evaluating the effects of TZDs on athero-
clerosis progression in diabetic patients (8,9). The clin-
cal implications of the study, however, are not extremely
lear at present, particularly in view of the neutral effects
f ramipril and the modest effects of rosiglitazone on
IMT in pre-diabetic patients found in the trial. Because
osiglitazone in particular is under close scrutiny after the
1esults of the meta-analysis by Nissen and Wolski in 2007
11) and TZDs in general continue to be monitored in
iew of reports showing that these drugs can increase the
isk for heart failure (15), the possible clinical application
f the STARR findings remains uncertain.
Despite the beneficial actions of TZDs in clinical and
xperimental studies in diabetic and nondiabetic populations—
ncluding the modest findings reported in STARR—the true
ffects of these drugs on ischemic CV events and all-cause
ortality and their role in clinical practice regarding CV
isease prevention still require further ad hoc investigation.
erhaps the development of new pharmacological agents able
o overcome the limitations of TZDs, particularly in relation to
heir potentially adverse CV effects, and a better understanding
f the mechanisms leading to CV events in pre-diabetic
ndividuals might offer better options for patient management
n the not so distant future.
eprint requests and correspondence: Prof. Juan Carlos Kaski,
ardiac and Vascular Sciences, St. George’s University of London,
ranmer Terrace, London SW17 0RE, United Kingdom. E-mail:
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